WASHINGTON, D.C. (November 2, 2017) – Pharmaceutical Research and Manufacturers of America (PhRMA) president and CEO Stephen J. Ubl issued the following statement:
“Solving the current opioid crisis requires a comprehensive approach that balances legitimate patient access for those in need with new measures that will prevent drug abuse and diversion. We applaud the President’s Commission on Combatting Drug Addiction and Opioid Abuse for putting forth a wide range of policy solutions to address this growing crisis. PhRMA shares the Commission’s goal of preventing addiction before it starts. We support mandatory, ongoing prescriber training to inform appropriate treatment for patients with legitimate need. We also support efforts to further strengthen prescription drug monitoring programs and law enforcement efforts to crack down on counterfeit fentanyl and illegal drugs.
“PhRMA is working with the National Institutes of Health (NIH) and National Institute on Drug Abuse (NIDA) to establish a public-private partnership that will advance the development of non-addictive pain treatment options, as well as new treatments for addiction and overdose. Currently, however, too many patients face insurance barriers to the care they need to prevent or overcome addiction or address mental health issues. We commend the Commission for expanding its recommendations to improve access to medicines that reduce the potential for abuse and medication assisted treatment for addiction recovery.
“PhRMA is committed to continuing to work with the Administration, health care stakeholders and others to craft a multifaceted solution to this multifaceted problem.”
The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research companies, which are devoted to discovering and developing medicines that enable patients to live longer, healthier, andmore productive lives. Since 2000, PhRMA member companies have invested more than $600 billion in the search for new treatments and cures, including an estimated $65.5 billion in 2016 alone.